Multi-purpose prevention technologies (MPTs) that aim to simultaneously prevent 12 unintended pregnancy, human immunodeficiency virus type 1 (HIV-1) infection and 13 other sexually transmitted infections (STIs) are among the most innovative and complex 14 products currently in development within women's sexual and reproductive healthcare. In 15 this review article, MPTs are placed within the wider context of combination products, 16 combination drug products and multi-indication products. The current MPT product 17 landscape is mapped and assessed with reference to existing products for the 18 corresponding single indications, before identifying the gaps in the current MPT product 19 pipeline and highlighting priority products and challenges moving forward.
Introduction
Since 2010, following the first encouraging data to emerge from clinical testing of an 22 antiretroviral-based HIV microbicide candidate 1 , there has been extensive talk, 23 consideration and early stage development around next generation products, termed 24 'multipurpose prevention technologies ' (MPTs) , that aim to combine HIV prevention 25 with prevention of unintended pregnancy and/or prevention/treatment of other sexually 26 transmitted infections (STIs) and reproductive tract infections (RTIs) . In addition to the 27 significant number of agenda-setting and commentary/review articles published on 28 MPTs, 2-10 there has also been a limited number of original research articles describing 29 new MPT concepts. [11] [12] [13] [14] [15] MPTs are not a new product class, despite the new (and 30 somewhat confusing) name. Male condoms, which offer effective barrier protection 31 against pregnancy, HIV and other STIs, have been used for more than 400 years, and 32 their female counterparts have been available since the 1980s. However, despite their 33 effectiveness, condoms are often not used consistently and correctly and have clear 34 limitations for women. Therefore, there is an urgent need for new and innovative MPT 35 products that offer women in particular greater choice and improved acceptability in 36 controlling their sexual and reproductive health. 37 38 With recent interest focused almost exclusively on microbicidal-based (and, more 39 specifically, antiretroviral-based) strategies for prevention of sexual transmission of HIV, 40 newer MPT approaches have inevitably included at least one active pharmaceutical 41 ingredient (API), resulting in either a 'combination product' (CP) or a 'combination drug 42 product' (CDP), to use more conventional pharmaceutical regulatory terminology (Table   43 1, Figure 1 ). For example, the microbicide-releasing diaphragm device recently reported 44 is considered a 'combination product' (Table 1, Figure 2 ), comprising a medical device (a 45 cervical barrier diaphragm) coupled with an additional drug delivery function (controlled 46 release of an antiretroviral microbicide). 13 A vaginal ring device that provided 47 simultaneous sustained/controlled release of an antiretroviral, a contraceptive 48 progestogen and/or an anti-HSV drug would formally be classified as 'combination drug 49 products' (Table 1, Figure 1, Figure 2 ). 16, 17 Regulatory definitions of a 'medical device' 50 and a 'drug delivery device', for which there is often considerable confusion, are also 51 provided in Table 1 . in a fixed ratio of doses, that is both safe and effective and where each API contributes to 60 the overall therapeutic effect. For patients, these combination products often lead to 61 simplified therapy, improved clinical effectiveness, reduced incidence of adverse side 62 effect and increased adherence. [18] [19] [20] For pharmaceutical companies, CDPs also offer 63 excellent opportunities for life cycle management of marketed drug products. Currently 64 marketed CDPs are mapped in Figure 1 according to the number of APIs in the product 65 and the number of clinical conditions that the product is intended to treat. Unlike the vast majority of drug products that contain a single active and treat a single disease, marketed 67 CDPs comprise two, three and even four actives for treatment of a single disease, most 68 commonly HIV/AIDS, asthma, malaria, contraception, high blood pressure and 69 tuberculosis ( Figure 1 ). Examples of CDPs that are used in the treatment of two distinct 70 (but clinically related) diseases include Caduet ® /Envacar ® (containing atorvastatin and 71 amlodipine; used in the treatment of high cholesterol and high blood pressure, (ii) There is presently a distinct lack of interest/commitment in the development of non-135 antiretroviral HIV prevention methods, although this has not always been the case. What are the MPT product priorities moving forward? 192 A key consideration for future MPT products will be user adherence to the prescribed 193 regimen, a particularly pertinent issue for on-demand products. The importance of user 194 adherence is well understood and documented within the contraceptive field, where the 195 differences between actual-use and perfect-use failure rates are highly dependent on 196 whether the products are user-dependent (e.g. oral pill, diaphragm, vaginal ring) or non-197 user dependent (e.g. intrauterine device, injectable, implant, and sterilisation). 37,38 198 Growing concern over (lack of) adherence to experimental microbicide products and been submitted for the tenofovir/levonorgestrel vaginal ring. When they do eventually 220 make it to clinic, many complex hurdles and challenges will likely prevent a quick route 221 to market. For example, the same issues that may challenge antiretroviral-based HIV 222 prevention around the potential for development of resistant virus will also apply to MPT 223 products containing antiretrovirals. This is likely to fuel demand for sustained release 224 products that promote user adherence. Also, given the complexity of multi-indication combination products having constituent parts corresponding to drug products, medical 226 devices and biologics, MPTs will invariably involve unique and challenging regulatory 227 considerations. Regulatory challenges, considerations, and decisions will be product-228 specific as well as indication-specific. In both the EU and the US, a single regulatory 229 center will have primary jurisdiction for the MPT product, and assignment is based on the 230 product's primary mode of action (although quite how the primary mode of action will be 231 defined is still unclear for many product concepts). Other major challenges for MPTs a single dosage form comprising two or more active pharmaceutical ingredients (APIs); may target single or multiple (often related) disease states; in tablet or capsule form, combination drugs are referred to as 'polypill' or 'combopill'
'combination product' a product comprised of any combination of a drug and a device; a biological product and a device; a drug and a biological product; or a drug, device, and a biological product 'combination therapy', 'polytherapy' or 'polypharmacy'
use of more than one medication or therapy; most commonly used to treat a single disease; may involve administration of separate drug products or combination drug products; conditions treated with combination therapy include tuberculosis, leprosy, cancer, malaria, and HIV/AIDS; 'polypharmacy' is often defined as the use of five or more regular medications (more common in older patients).
'drug delivery device'
any device that provides delivery of one of more drug substances 'medical device' "any instrument, apparatus, appliance, software, material or other article, whether used alone or in combination, including the software intended by its manufacturer to be used specifically for diagnostic and/or therapeutic purposes and necessary for its proper application, intended by the manufacturer to be used for human beings for the purpose of: diagnosis, prevention, monitoring, treatment or alleviation of disease; diagnosis, monitoring, treatment, alleviation of or compensation for an injury or handicap; investigation, replacement or modification of the anatomy or of a physiological process; control of conception; and which does not achieve its principal intended action in or on the human body by pharmacological, immunological or metabolic means, but which may be assisted in its function by such means;" (Medical Devices Directive 93/42/EEC (MDD)) 'medicinal product' "any substance or combination of substances presented as having properties for treating or preventing disease in human beings; [or] any substance or combination of substances which may be used in or administered to human beings either with a view to restoring, correcting or modifying physiological functions by exerting a pharmacological, immunological or metabolic action, or to making a medical diagnosis." (European Union Directive 2004/27/EC) 'monotherapy' use of a single medication for treatment of a single disease 'multi-purpose prevention technology'
the term is exclusively used to describe technologies, preferably single-product technologies, that simultaneously address at least two of the following clinical needs: (i) prevention of unintended pregnancy, (ii) prevention of HIV, (iii) prevention or treatment of other sexually transmitted or reproductive tract infections
